Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 13th Preview)
-
Large global pharma-China partnership
Bristol Myers Squibb and Hengrui Pharma signed a global drug research pact spanning 13 programs across oncology, hematology and immunology, with $600 million upfront and up to $15.2 billion in total value. The agreement allocates China rights to Hengrui and ex-China rights to BMS, aligning both companies with a shared discovery and development plan. The deal extends a pattern of Western pharma leaning on China-based R&D capacity for early-stage pipeline replenishment. It also reflects how Big Pharma is restructuring partnership portfolios around modular, multi-asset collaborations. Executives framed the pact as expanding globalization of pipeline development while leveraging Hengrui’s internal R&D capabilities and BMS’s discovery infrastructure.
-
FDA leadership shake-up
Marty Makary resigned as FDA commissioner, with Kyle Diamantas stepping in as acting commissioner, according to multiple reports. The leadership change closes a tenure marked by rapid drug-development initiatives alongside internal turmoil, including high turnover in senior roles and criticism of unpredictable regulatory execution. Analysts noted uncertainty around FDA predictability during Makary’s term, with some companies reporting frustration tied to guidance shifts and review outcomes. Makary had championed measures intended to speed approvals, including a streamlined approach to ultra-rare disease frameworks and increased use of AI in review processes. The transition matters for biotech because FDA alignment on trial design and review expectations is a key driver of development timelines and risk.
-
Regulatory change: gene therapy definition in the UK
The UK’s MHRA opened a consultation proposing updates to the legal definition of gene therapies, aiming to reflect technological and manufacturing advances over the past two decades. The move targets how gene therapy is categorized under UK rules, which can affect compliance pathways and regulatory expectations for developers. The consultation comes as gene therapy platforms diversify beyond classic viral vector approaches, including newer delivery methods, manufacturing strategies and clinical-grade analytics. For biotech, the consultation signals that developers may need to reassess how their product classifications map to evolving MHRA definitions and oversight models.
-
Gene therapy safety investigation—death in trial
Capsida Biotherapeutics said it still lacks answers in its investigation into a child’s death in its CAP-002 gene therapy trial last September. The company said its efforts have been stymied because the hospital conducting the study has declined to share autopsy tissue samples. CAP-002 is designed as a brain-delivery gene therapy using engineered viruses intended to cross the blood-brain barrier. The case adds to scrutiny around patient safety and post-event transparency in neurotropic gene therapy programs. The update matters for the field because it highlights how investigations can be slowed by data access and underscores the importance of early governance around tissue and investigation artifacts.
-
Alzheimer’s diagnostics in Europe
Roche secured CE marking for its Elecsys plasma phosphorylated-tau 217 blood test to rule in and rule out amyloid pathology. The test, developed with Eli Lilly, adds another non-invasive option for clinicians to diagnose Alzheimer’s-related amyloid status following FDA action on a comparable blood test from Fujirebio. Roche’s move extends the company’s push into end-to-end oncology and neurodiagnostics solutions using blood-based biomarkers. It also increases competition in the rapid adoption of plasma tests for dementia staging and patient selection. For biotech and diagnostic developers, CE clearance reinforces that regulatory pathways for blood biomarkers are increasingly established across markets, enabling faster clinical workflow integration.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.